ArticleESMO real world data and digital oncology2025

Time to next treatment to evaluate the therapeutic sequence after first- or second-line CDK4/6 inhibitors of hormone receptor-positive, HER2-negative advanced breast cancer in Italy: a retrospective/prospective observational trial GOIRC-04-2019.

L Moscetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.